ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Analyst Earnings Estimates
NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 243.2M 75.85% | 240.7M -1.03% | 3.551M -98.52% | 159.1M 4,380.43% | 253.95M 59.62% | 340.61M 34.12% | 413.9M 21.52% | 920.43M 122.38% | 1.568B 70.36% | 2.314B 47.58% | 3.002B 29.73% | |
| EBITDA YoY % growth | -168.1M -19.47% | -192.5M -14.52% | -582.485M -202.59% | -557.134M 4.35% | -597.262M -7.20% | -513.772M 13.98% | -465.12M 9.47% | -174.012M 62.59% | 393.72M 326.26% | N/A | N/A | |
| EBIT YoY % growth | -178.5M -19.80% | -205M -14.85% | -601.08M -193.21% | -416.704M 30.67% | -514.523M -23.47% | -457.335M 11.11% | -400.738M 12.38% | -4.998M 98.75% | 558.35M 11,271.47% | 1.157B 107.22% | 1.725B 49.09% | |
| Operating Margin | -73.40% | -85.17% | -16,927.06% | -261.91% | -202.61% | -134.27% | -96.82% | -0.54% | 35.61% | 50.00% | 57.46% | |
| EPS YoY % growth | -1.68 -23.53% | -1.92 -14.29% | -5.01 -160.94% | -3.80 24.15% | -3.84 -1.14% | -3.17 17.41% | -2.94 7.46% | 0.73 124.77% | 5.77 693.03% | 13.94 141.57% | 20.07 43.98% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 61.13% | -0.89 35.26% | -0.90 34.18% | 0.22 116.14% | -1.26 -219.04% | -1.25 -40.44% | -1.25 -39.14% |
| Revenue Q2Q % growth | 36.083M | 56.1M | 58.155M | 218.52M 8,640.80% | 14.79M -59.01% | 17.34M -69.09% | 18.36M -68.43% |
| EBITDA Q2Q % growth | 21.642M 118.43% | -110.286M 32.16% | -150.15M -4.56% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -81.743M 35.22% | -117.511M 33.29% | -126.43M 22.05% | 39.672M 124.58% | -165.919M -102.98% | -163.742M -39.34% | -162.87M -28.82% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -1.39 -12.10% | -0.45 | -0.94 | -211.36% |
| Q4 2024 Q2Q % growth | -1.37 -34.31% | -1.07 | -0.30 | -28.19% |
| Q3 2024 Q2Q % growth | -1.38 -43.75% | -0.56 | -0.82 | -145.24% |
| Q2 2024 Q2Q % growth | -1.02 -326.67% | -0.17 | -0.85 | -515.69% |
| Q1 2024 Q2Q % growth | -1.24 -217.95% | -0.84 | -0.40 | -48.25% |
| Q4 2023 Q2Q % growth | -1.02 -25.93% | -0.62 | -0.40 | -65.77% |
| Q3 2023 Q2Q % growth | -0.96 -41.18% | -0.67 | -0.29 | -44.13% |
| Q2 2023 Q2Q % growth | 0.45 9.76% | -0.65 | 1.10 | 168.84% |
| Q1 2023 Q2Q % growth | -0.39 35.00% | 0.45 | -0.84 | -187.62% |
| Q4 2022 Q2Q % growth | -0.81 -32.79% | -0.17 | -0.64 | -379.95% |
| Q3 2022 Q2Q % growth | -0.68 -134.48% | -0.52 | -0.16 | -31.80% |
| Q2 2022 Q2Q % growth | 0.41 257.69% | -0.08 | 0.49 | 596.25% |
| Q1 2022 Q2Q % growth | -0.60 -200.00% | -0.46 | -0.14 | -31.60% |
| Q4 2021 Q2Q % growth | -0.61 -27.08% | -0.11 | -0.50 | -467.08% |
| Q3 2021 Q2Q % growth | -0.29 -123.08% | -0.20 | -0.09 | -44.10% |
| Q2 2021 Q2Q % growth | -0.26 -30.00% | -0.13 | -0.13 | -94.14% |
| Q1 2021 Q2Q % growth | -0.20 -566.67% | 0.12 | -0.32 | -266.32% |
| Q4 2020 Q2Q % growth | -0.48 -536.36% | 0.12 | -0.60 | -504.42% |
| Q3 2020 Q2Q % growth | -0.13 -161.90% | -0.12 | -0.01 | -9.87% |
| Q2 2020 Q2Q % growth | -0.20 -183.33% | -0.11 | -0.09 | -80.07% |
| Q1 2020 Q2Q % growth | -0.03 -123.08% | -0.01 | -0.02 | -311.93% |
| Q4 2019 Q2Q % growth | 0.11 | 0.17 | -0.06 | -34.36% |
| Q3 2019 Q2Q % growth | 0.21 | 0.30 | -0.09 | -29.81% |
| Q2 2019 Q2Q % growth | 0.24 | 0.20 | 0.04 | 21.71% |
| Q1 2019 Q2Q % growth | 0.13 | 0.55 | -0.42 | -76.32% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 2.5M -29.60% | 74.205M | -71.705M | -96.63% |
| Q4 2024 Q2Q % growth | -100.00% | 65.099M | -65.099M | -100.00% |
| Q3 2024 Q2Q % growth | -100.00% | 53.688M | -53.688M | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 65.147M | -65.147M | -100.00% |
| Q1 2024 Q2Q % growth | 3.551M -94.32% | 30.101M | -26.55M | -88.20% |
| Q4 2023 Q2Q % growth | 16.097M -49.06% | 51.743M | -35.646M | -68.89% |
| Q3 2023 Q2Q % growth | 15.825M -51.16% | 50.169M | -34.344M | -68.46% |
| Q2 2023 Q2Q % growth | 146.267M -3.64% | 46.389M | 99.878M | 215.31% |
| Q1 2023 Q2Q % growth | 62.5M 128.10% | 165.77M | -103.27M | -62.30% |
| Q4 2022 Q2Q % growth | 31.6M -17.49% | 51.453M | -19.853M | -38.58% |
| Q3 2022 Q2Q % growth | 32.4M -29.41% | 56.332M | -23.932M | -42.48% |
| Q2 2022 Q2Q % growth | 151.8M 362.80% | 111.09M | 40.71M | 36.65% |
| Q1 2022 Q2Q % growth | 27.4M 28.64% | 52.065M | -24.665M | -47.37% |
| Q4 2021 Q2Q % growth | 38.3M 403.95% | 57.91M | -19.61M | -33.86% |
| Q3 2021 Q2Q % growth | 45.9M 67.52% | 38.267M | 7.633M | 19.95% |
| Q2 2021 Q2Q % growth | 32.8M 39.57% | 38.451M | -5.651M | -14.70% |
| Q1 2021 Q2Q % growth | 21.3M -27.80% | 77.076M | -55.776M | -72.36% |
| Q4 2020 Q2Q % growth | 7.6M -82.45% | 50.227M | -42.627M | -84.87% |
| Q3 2020 Q2Q % growth | 27.4M -35.83% | 29.49M | -2.09M | -7.09% |
| Q2 2020 Q2Q % growth | 23.5M -51.14% | 22.175M | 1.325M | 5.98% |
| Q1 2020 Q2Q % growth | 29.5M -14.99% | 30.09M | -590K | -1.96% |
| Q4 2019 Q2Q % growth | 43.3M | 42.311M | 989K | 2.34% |
| Q3 2019 Q2Q % growth | 42.7M | 55.454M | -12.754M | -23.00% |
| Q2 2019 Q2Q % growth | 48.1M | 43.848M | 4.252M | 9.70% |
| Q1 2019 Q2Q % growth | 34.7M | 73.032M | -38.332M | -52.49% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 67.8% | 50.33% | -13.37% | 11.8% |
| Revenue | 38.56% | 47.55% | -1.89% | -20.54% |